---
title: "JAFRON released its performance for the first three quarters, with a net profit attributable to the parent company of 453 million yuan, a decrease of 42.75%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263340862.md"
description: "According to the Zhitong Finance APP, JAFRON released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.556 billion yuan, a year-on-year decrease of 29.13%. The net profit attributable to shareholders of the listed company was 453 million yuan, a year-on-year decrease of 42.75%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 438 million yuan, a year-on-year decrease of 41.87%. The basic earnings per share were 0.59 yuan"
datetime: "2025-10-29T16:11:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263340862.md)
  - [en](https://longbridge.com/en/news/263340862.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263340862.md)
generator: "portal-rs"
---

# JAFRON released its performance for the first three quarters, with a net profit attributable to the parent company of 453 million yuan, a decrease of 42.75%

According to the Zhitong Finance APP, JAFRON (300529.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.5556 billion yuan, a year-on-year decrease of 29.13%. The net profit attributable to shareholders of the listed company was 453 million yuan, a year-on-year decrease of 42.75%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 438 million yuan, a year-on-year decrease of 41.87%. The basic earnings per share were 0.59 yuan

### Related Stocks

- [300529.CN](https://longbridge.com/en/quote/300529.CN.md)

## Related News & Research

- [Cofoe Medical FY26 H1 profit climbs 21.9% to RMB 203.2 million; revenue rises 38.5% to RMB 2.07 billion](https://longbridge.com/en/news/297291709.md)
- [MedicalRite Announces COVID-19 & Flu Combo Test for Better Health](https://longbridge.com/en/news/297204162.md)
- [09:00 ETSickSlip Expands Beyond Doctor's Notes Into Sports Physicals, HSA/FSA Letters, and Dive Medicals](https://longbridge.com/en/news/297329784.md)
- [SynAct Pharma Expands Resomelagon’s Potential With New Preclinical Inflammation Data](https://longbridge.com/en/news/297303959.md)
- [Elicera Therapeutics plans first ELC-401 glioblastoma clinical trial after positive Swedish MPA feedback](https://longbridge.com/en/news/297272556.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**